Background
Materials and methods
Patients
Clinicopathologic characteristics | All cases (n = 210) | CTHRC1 expression | P-value | |
---|---|---|---|---|
Low (n = 137) | High (n = 73) | |||
Gender | ||||
Male | 114 | 80 | 34 | 0.111 |
Female | 96 | 57 | 39 | |
Age (years) | ||||
≤ 50 | 64 | 39 | 25 | 0.432 |
> 50 | 146 | 98 | 48 | |
Smoking | ||||
Yes | 43 | 33 | 10 | 0.105 |
No | 167 | 104 | 63 | |
Tumor differentiation | ||||
Well | 10 | 7 | 3 | 0.172 |
Moderately | 181 | 114 | 67 | |
Poorly | 19 | 16 | 3 | |
Clinical stage | ||||
I | 130 | 102 | 28 | < 0.001 |
II | 25 | 11 | 14 | |
III | 36 | 18 | 18 | |
IV | 19 | 6 | 13 | |
T classification | ||||
T1 | 76 | 53 | 23 | 0.025 |
T2 | 112 | 76 | 36 | |
T3 | 12 | 5 | 7 | |
T4 | 10 | 3 | 7 | |
N classification | ||||
N0 | 146 | 107 | 39 | 0.001 |
N1 | 21 | 9 | 12 | |
N2 | 33 | 18 | 15 | |
N3 | 10 | 3 | 7 | |
M classification | ||||
M0 | 195 | 132 | 63 | 0.011 |
M1 | 15 | 5 | 10 |
Immunohistochemistry (IHC)
Gene set enrichment analysis (GSEA)
Cell lines
Stable clone establishment
Western blotting (WB)
Total RNA extraction and Quantitative Real-time PCR (qRT-PCR)
Statistical analysis
Results
Clinicopathologic patient characteristics
Association between CTHRC1 expression and clinicopathologic characteristics in LUAD
Association between CTHRC1 expression and patient survival in LUAD
Variables | OS | PFS | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
Gender | 1.067 | 0.742–1.534 | 0.727 | 1.090 | 0.759–1.566 | 0.640 |
Age | 1.050 | 1.032–1.069 | < 0.001 | 1.504 | 0.993–2.278 | 0.054 |
Smoking | 0.990 | 0.637–1.541 | 0.966 | 0.981 | 0.631–1.525 | 0.931 |
Tumor differentiation | 0.724 | 0.450–1.166 | 0.184 | 0.897 | 0.574–1.400 | 0.631 |
Clinical stage | 2.572 | 2.112–3.132 | < 0.001 | 2.481 | 2.034–3.025 | < 0.001 |
T classification | 1.414 | 1.106–1.808 | 0.006 | 1.163 | 0.900–1.504 | 0.248 |
N classification | 1.935 | 1.608–2.330 | < 0.001 | 1.793 | 1.480–2.172 | < 0.001 |
M classification | 7.165 | 3.673–13.976 | < 0.001 | 6.873 | 3.432–13.766 | < 0.001 |
CTHRC1 expression | 2.300 | 1.600–3.308 | < 0.001 | 2.643 | 1.827–3.822 | < 0.001 |
VEGF expression | 2.733 | 1.860–4.017 | < 0.001 | 3.673 | 2.485–5.429 | < 0.001 |
MVD count | 2.122 | 1.476–3.050 | < 0.001 | 1.881 | 1.305–2.711 | 0.001 |
Variables | OS | PFS | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
Gender | 1.074 | 0.703–1.643 | 0.740 | 1.204 | 0.790–1.834 | 0.389 |
Age | 3.223 | 1.917–5.418 | < 0.001 | 2.097 | 1.344–3.273 | 0.001 |
Smoking | 0.934 | 0.563–1.588 | 0.833 | 0.892 | 0.548–1.451 | 0.644 |
Tumor differentiation | 0.946 | 0.563–1.588 | 0.833 | 1.318 | 0.802–2.164 | 0.276 |
Clinical stage | 2.996 | 2.135–4.204 | < 0.001 | 3.267 | 2.302–4.638 | < 0.001 |
T classification | 0.805 | 0.673–1.016 | 0.067 | 0.730 | 0.576–0.925 | 0.009 |
N classification | 0.911 | 0.665–1.250 | 0.565 | 0.796 | 0.576–1.100 | 0.167 |
M classification | 1.433 | 0.628–3.269 | 0.393 | 1.163 | 0.504–2.686 | 0.732 |
CTHRC1 expression | 1.097 | 1.029–1.170 | 0.004 | 1.133 | 1.061–1.211 | < 0.001 |
VEGF expression | 0.987 | 0.927–1.051 | 0.680 | 1.033 | 0.970–1.100 | 0.313 |
MVD count | 1.015 | 0.999–1.030 | 0.060 | 1.005 | 0.990–1.020 | 0.507 |
Association between CTHRC1 expression and tumor angiogenesis markers
Characteristics | CTHRC1 expression | P-value | |
---|---|---|---|
Low (n = 137) | High (n = 73) | ||
VEGF expression | |||
Low | 85 (80.2%) | 21 (19.8%) | < 0.001a |
High | 52 (50.0%) | 52 (50.0%) | |
MVD counts | |||
Low | 96 (71.6%) | 38 (28.4%) | 0.011a |
High | 41 (53.9%) | 35 (46.1%) |
Enhanced CTHRC1 expression can promote VEGF expression in LUAD in vitro
Combining CTHRC1 expression with tumor angiogenesis markers to construct a predictive model
CTHRC1 expression concomitant with VEGF expression and MVD predicts prognosis in LUAD
Variables | OS | PFS | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
Gender | 0.880 | 0.571–1.357 | 0.564 | 1.088 | 0.713–1.662 | 0.695 |
Age | 1.062 | 1.042–1.084 | < 0.001 | 1.029 | 1.010–1.049 | 0.003 |
Smoking | 1.071 | 0.655–1.752 | 0.784 | 0.878 | 0.541–1.427 | 0.601 |
Tumor differentiation | 0.942 | 0.557–1.593 | 0.823 | 1.411 | 0.869–2.289 | 0.164 |
Clinical stage | 2.792 | 1.990–3.918 | < 0.001 | 3.165 | 2.236–4.480 | < 0.001 |
T classification | 0.840 | 0.664–1.063 | 0.146 | 0.727 | 0.575–0.920 | 0.008 |
N Classification | 0.935 | 0.678–1.288 | 0.680 | 0.766 | 0.554–1.059 | 0.107 |
M Classification | 1.633 | 0.729–3.661 | 0.233 | 1.318 | 0.869–2.289 | 0.517 |
The predictive model | 1.795 | 1.291–2.496 | 0.001 | 2.301 | 1.671–3.168 | < 0.001 |